Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy

Project Title Mini-Sentinel: Summary of Antidiabetic Agent Use During Pregnancy
Date Posted
Thursday, January 2, 2020
Project ID
to07_add_preg_ahr_wp003
Status
Complete
Deliverables
Mini-Sentinel Modular Program Report: Summary of Antidiabetic Agent Use During Pregnancy
Related Links
Use of Antidiabetic Drugs During Pregnancy among U.S. Women with Livebirth Deliveries in the Mini-Sentinel System
Description

This report contains estimates of the prevalence of antidiabetic agent use among females 10 to 54 years of age who delivered a live-born infant between January 1, 2001 and December 31, 2013 in the Mini-Sentinel Distributed Database (MSDD). Results for antidiabetic agent use are also presented for a matched comparator cohort with no live-birth deliveries during the request period.

Data from January 1, 2001 to December 31, 2013, from 15 Data Partners contributing to the MSDD were included in this report. This request was distributed to Data Partners on May 14, 2015.

Medical Product
alpha-glucosidase inhibitor
amylin analog
biguanide
dipeptidyl peptidase-4 (DPP-4) inhibitor
glucagon-like peptide-1 (GLP-1) receptor agonist
injectable insulin
meglitinide analog
sulfonylurea
thiazolidinedione
Health Outcome
exposure in pregnancy
Population / Cohort
Females 10 to 54 years of age
Time Period
January 1, 2001 - December 31, 2013
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
CDER
Scroll to Top